Design, Synthesis, and Biological Evaluation of Novel Quinoxaline Derivatives as Anticancer Agents Targeting EGFR Pathways
International Journal of Drug Delivery Technology · 01.07.2026 · 16 (60s)
DOI: 10.25258/ijddt.16.60s.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.07.2026. Verfasst von Komal kriti und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Cancer remains a leading cause of mortality worldwide, demanding the discovery of novel therapeutic agents that can overcome drug resistance and improve patient outcomes. The epidermal growth factor receptor (EGFR) has been established as a critical target in oncology due to its central role in regulating proliferation, survival, and metastasis. In this study, novel quinoxaline derivatives were designed, synthesized, and evaluated for their anticancer potential as EGFR inhibitors. Computational docking analyses revealed favorable binding affinities, with strong interactions involving key EGFR residues such as Met793 and Phe723, supporting their predicted inhibitory activity. The synthesized compounds were characterized by FT-IR, NMR, and HRMS to confirm structural integrity. In vitro cytotoxicity assays demonstrated significant growth inhibition across cancer cell lines (A549, MCF-7, HCT116), with selectivity indices indicating minimal toxicity toward normal fibroblasts. EGFR inhibition assays confirmed low micromolar IC₅₀ values, accompanied by downregulation of phosphorylated EGFR in western blot experiments. Mechanistic studies further established that apoptosis induction was mediated by mitochondrial dysfunction, ROS generation, and caspase activation. Structure–activity relationship (SAR) analysis highlighted the importance of unsubstituted aromatic rings, electron-withdrawing substituents, and CH₂ linkers for potency. Comparative evaluation with gefitinib showed that some derivatives achieved comparable or superior activity, underscoring their potential to overcome current therapeutic limitations. These results suggest that quinoxaline scaffolds represent a promising platform for the development of next-generation EGFR-targeted anticancer agents.
Zitieren
APA
kriti, K., Veera, S. S., Solanki, N., Saqib, M., Gawade, V., Wasiullah, M., Bhutkar, K. G., & Solanki, S. (2026). Design, Synthesis, and Biological Evaluation of Novel Quinoxaline Derivatives as Anticancer Agents Targeting EGFR Pathways. International Journal of Drug Delivery Technology, 16(60s). https://doi.org/10.25258/ijddt.16.60s.1
Vancouver
kriti K, Veera SS, Solanki N, Saqib M, Gawade V, Wasiullah M, et al. Design, Synthesis, and Biological Evaluation of Novel Quinoxaline Derivatives as Anticancer Agents Targeting EGFR Pathways. International Journal of Drug Delivery Technology. 2026;16(60s). doi:10.25258/ijddt.16.60s.1
BibTeX
@article{kriti2026,
author = {kriti, Komal and Veera, Swamy Sabharinadh and Solanki, Nikunj and Saqib, Mohammad and Gawade, Vaibhav and Wasiullah, Mohd and Bhutkar, Ketan Girish and Solanki, Sonal},
title = {Design, Synthesis, and Biological Evaluation of Novel Quinoxaline Derivatives as Anticancer Agents Targeting EGFR Pathways},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {60s},
doi = {10.25258/ijddt.16.60s.1}
}
EUVIMED